<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823355</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-J01</org_study_id>
    <nct_id>NCT00823355</nct_id>
  </id_info>
  <brief_title>Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies</brief_title>
  <official_title>A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in
      each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate
      pharmacokinetics (PK) of oral BCX1777.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety profile and tolerability of oral BCX1777 in patients with recurrent or refractory T/ NK-cell malignancies.</measure>
    <time_frame>March 2010</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate pharmacokinetics (PK) of oral BCX1777</measure>
    <time_frame>March 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacodynamics (PD) of oral BCX1777</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the plasma level of BCX1777 with plasma 2'-deoxyguanosine (dGuo)</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of oral BCX1777</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze cell surface marker in peripheral blood mononuclear cell</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Recurrent or Refractory T/NK-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>BCX1777</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
    <description>Cohort 1: 100mg / body (1 x 100mg tablet once daily)</description>
    <arm_group_label>BCX1777</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
    <description>Cohort 2: 200mg / body (2 x 100mg tablets once daily)</description>
    <arm_group_label>BCX1777</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
    <description>Cohort 3: 300mg / body (3 x 100mg tablets once daily)</description>
    <arm_group_label>BCX1777</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
    <description>Cohort 4: 400mg / body (4 x 100mg tablets once daily)</description>
    <arm_group_label>BCX1777</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented with histopathological diagnosis from biopsy, T/NK-cell
             malignancies (WHO classification). Precursor T-cell lymphoblastic leukemia/lymphoma
             (T-ALL/T-LBL) should be excluded in this study

          -  A patient with recurrent, relapse or refractory T/NK-cell malignancies who has
             received at lease one chemotherapeutic regimen

          -  Age 20 or greater

          -  Eastern Cooperative Oncology Group(ECOG) performance status:0,1.

          -  Able to be hospitalized at least for 15 days from the first dose

          -  In the case of subject with tumor cell rate of ≤25% in bone marrow, a patient who
             satisfies both of the following criteria.

               -  Neutrophil count: ≥1,200/mm3

               -  Platelet count: ≥75,000/mm3

                    -  In the case of CTCL, the tumor cell rate is handled as ≤25%.

          -  Adequate Liver function: AST, ALT ≤ 5.0 x upper limit of normal (ULN)

          -  Adequate Renal function: Creatinine Clearance (using cockcroft-Gault formula) ≥
             50mL/min

          -  Life expectancy of at least 3 months

          -  A patient who has given a written informed consent prior to the start of procedures
             proper to this study.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cyuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

